Because PCSK9 genetic gain-of-function mutations are associated with hypercholesterolemia, the pharmacological inhibition of PCSK9 is considered a promising route of intervention for preventing cardiovascular diseases [16]. This evidence concerns the gene PCSK9 and cardiovascular disorder.